Cargando…
The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival
BACKGROUND: Lung cancer causes approximately one million deaths each year worldwide and protein p53 has been shown to be involved in the intricate processes regulating response to radiation and/or chemotherapeutic treatment. Consequently, since antibodies against p53 (anti-p53 antibodies) are associ...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC517936/ https://www.ncbi.nlm.nih.gov/pubmed/15367333 http://dx.doi.org/10.1186/1471-2407-4-66 |
_version_ | 1782121796966809600 |
---|---|
author | Bergqvist, Michael Brattström, Daniel Larsson, Anders Hesselius, Patrik Brodin, Ola Wagenius, Gunnar |
author_facet | Bergqvist, Michael Brattström, Daniel Larsson, Anders Hesselius, Patrik Brodin, Ola Wagenius, Gunnar |
author_sort | Bergqvist, Michael |
collection | PubMed |
description | BACKGROUND: Lung cancer causes approximately one million deaths each year worldwide and protein p53 has been shown to be involved in the intricate processes regulating response to radiation and/or chemotherapeutic treatment. Consequently, since antibodies against p53 (anti-p53 antibodies) are associated with mutations within the p53 gene it seems likely that these antibodies could, hypothetically, be correlated with prognosis. METHODS: Serum samples from patients with non-small cell lung cancer (NSCLC) admitted to the Department of Oncology, University Hospital, Uppsala, Sweden, during 1983–1996 were studied. Anti-p53 abs were measured using a sandwich ELISA (Dianova, Hamburg, Germany). RESULTS: The present study included 84 patients with stage IIIA-IV (advanced NSCLC). At least three serum samples from each patient were collected and altogether 529 serum samples were analysed for the presence of anti-p53 antibodies. The median value of anti-p53 antibodies was 0.06 (range 0 – 139.8). Seventeen percent of investigated NSCLC first serum samples (n = 84) expressed elevated levels of anti-p53 antibodies. Anti-p53 antibodies were not correlated to tumour volume or platelets. Survival analysis showed that anti-p53 antibodies were not associated with survival as revealed by univariate analysis (p = 0.29). However, patients with adenocarcinoma had a significantly poorer survival if they expressed anti-p53 antibodies (p = 0.01), whereas this was not found for patients with squamous cell carcinoma (p = 0.13). In patients where the blood samples were collected during radiation therapy, a statistically significant correlation towards poorer survival was found (p = 0.05) when elevated anti-p53 antibodies levels were present. No correlations to survival were found for serum samples collected prior to radiation therapy, during chemotherapy, or during follow-up. When anti-p53 antibodies were measured continuously, no increase in median anti-p53 values was observed the closer the individual patient come to death. CONCLUSION: The result of the present retrospective study indicates that anti-p53 antibodies are not suitable for predictions concerning selection of patients with a more favourable outcome. Further prospective studies are, though, needed to fully elucidate this issue. |
format | Text |
id | pubmed-517936 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-5179362004-09-24 The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival Bergqvist, Michael Brattström, Daniel Larsson, Anders Hesselius, Patrik Brodin, Ola Wagenius, Gunnar BMC Cancer Research Article BACKGROUND: Lung cancer causes approximately one million deaths each year worldwide and protein p53 has been shown to be involved in the intricate processes regulating response to radiation and/or chemotherapeutic treatment. Consequently, since antibodies against p53 (anti-p53 antibodies) are associated with mutations within the p53 gene it seems likely that these antibodies could, hypothetically, be correlated with prognosis. METHODS: Serum samples from patients with non-small cell lung cancer (NSCLC) admitted to the Department of Oncology, University Hospital, Uppsala, Sweden, during 1983–1996 were studied. Anti-p53 abs were measured using a sandwich ELISA (Dianova, Hamburg, Germany). RESULTS: The present study included 84 patients with stage IIIA-IV (advanced NSCLC). At least three serum samples from each patient were collected and altogether 529 serum samples were analysed for the presence of anti-p53 antibodies. The median value of anti-p53 antibodies was 0.06 (range 0 – 139.8). Seventeen percent of investigated NSCLC first serum samples (n = 84) expressed elevated levels of anti-p53 antibodies. Anti-p53 antibodies were not correlated to tumour volume or platelets. Survival analysis showed that anti-p53 antibodies were not associated with survival as revealed by univariate analysis (p = 0.29). However, patients with adenocarcinoma had a significantly poorer survival if they expressed anti-p53 antibodies (p = 0.01), whereas this was not found for patients with squamous cell carcinoma (p = 0.13). In patients where the blood samples were collected during radiation therapy, a statistically significant correlation towards poorer survival was found (p = 0.05) when elevated anti-p53 antibodies levels were present. No correlations to survival were found for serum samples collected prior to radiation therapy, during chemotherapy, or during follow-up. When anti-p53 antibodies were measured continuously, no increase in median anti-p53 values was observed the closer the individual patient come to death. CONCLUSION: The result of the present retrospective study indicates that anti-p53 antibodies are not suitable for predictions concerning selection of patients with a more favourable outcome. Further prospective studies are, though, needed to fully elucidate this issue. BioMed Central 2004-09-14 /pmc/articles/PMC517936/ /pubmed/15367333 http://dx.doi.org/10.1186/1471-2407-4-66 Text en Copyright © 2004 Bergqvist et al; licensee BioMed Central Ltd. |
spellingShingle | Research Article Bergqvist, Michael Brattström, Daniel Larsson, Anders Hesselius, Patrik Brodin, Ola Wagenius, Gunnar The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival |
title | The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival |
title_full | The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival |
title_fullStr | The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival |
title_full_unstemmed | The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival |
title_short | The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival |
title_sort | role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC517936/ https://www.ncbi.nlm.nih.gov/pubmed/15367333 http://dx.doi.org/10.1186/1471-2407-4-66 |
work_keys_str_mv | AT bergqvistmichael theroleofcirculatingantip53antibodiesinpatientswithadvancednonsmallcelllungcancerandtheircorrelationtoclinicalparametersandsurvival AT brattstromdaniel theroleofcirculatingantip53antibodiesinpatientswithadvancednonsmallcelllungcancerandtheircorrelationtoclinicalparametersandsurvival AT larssonanders theroleofcirculatingantip53antibodiesinpatientswithadvancednonsmallcelllungcancerandtheircorrelationtoclinicalparametersandsurvival AT hesseliuspatrik theroleofcirculatingantip53antibodiesinpatientswithadvancednonsmallcelllungcancerandtheircorrelationtoclinicalparametersandsurvival AT brodinola theroleofcirculatingantip53antibodiesinpatientswithadvancednonsmallcelllungcancerandtheircorrelationtoclinicalparametersandsurvival AT wageniusgunnar theroleofcirculatingantip53antibodiesinpatientswithadvancednonsmallcelllungcancerandtheircorrelationtoclinicalparametersandsurvival AT bergqvistmichael roleofcirculatingantip53antibodiesinpatientswithadvancednonsmallcelllungcancerandtheircorrelationtoclinicalparametersandsurvival AT brattstromdaniel roleofcirculatingantip53antibodiesinpatientswithadvancednonsmallcelllungcancerandtheircorrelationtoclinicalparametersandsurvival AT larssonanders roleofcirculatingantip53antibodiesinpatientswithadvancednonsmallcelllungcancerandtheircorrelationtoclinicalparametersandsurvival AT hesseliuspatrik roleofcirculatingantip53antibodiesinpatientswithadvancednonsmallcelllungcancerandtheircorrelationtoclinicalparametersandsurvival AT brodinola roleofcirculatingantip53antibodiesinpatientswithadvancednonsmallcelllungcancerandtheircorrelationtoclinicalparametersandsurvival AT wageniusgunnar roleofcirculatingantip53antibodiesinpatientswithadvancednonsmallcelllungcancerandtheircorrelationtoclinicalparametersandsurvival |